Targeted radiosensitisation by pegylated liposome-encapsulated 3′, 5′-O-dipalmitoyl 5-iodo-2′-deoxyuridine in a head and neck cancer xenograft model

British Journal of Cancer

Volumn 91, Issue 2, 2004, Pages 366-373

  Harrington, K J ^a,b   Syrigos, K N ^a   Uster, P S ^c   Zetter, A ^c   Lewanski, C R ^a   Gullick, W J ^a   Vile, R G ^d   Stewart, J S W ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ALZA CORPORATION   (United States)

^d MAYO CLINIC   (United States)

Author keywords

5 iodo 2 deoxyuridine; Pegylated liposome; Prodrug; Radiosensitiser

Indexed keywords

5 HYDROXYMETHYLDEOXYURIDINE; IDOXURIDINE DERIVATIVE; PEGYLATED LIPOSOMAL 3',5' O DIPALMITOYL 5 IODO 2' DEOXYRUDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CELL STRAIN KB; CONTROLLED STUDY; ENCAPSULATION; FEMALE; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIPOPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; XENOGRAFT;

EID: 3843144007     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601958     Document Type: Article

References (36)

1. Cook JA, Glass J, Lebovics R, Bobo H, Pass H, DeLaney TF, Oldfield EH, Mitchell JB, Glatstein E, Goffman TE (1992) Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumours, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine. Cancer Res 52: 719-725
2. Epstein AH, Lebovics RS, Goffman T, Teague D, Fuetsch ES, Glatstein E, Okunieff P, Cook JA (1994) Treatment of locally advanced cancer of the head and neck with 5′-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labelling and thymidine replacement. J Natl Cancer Inst 86: 1775-1780
3. Fornace Jr AJ, Dobson PP, Kinsella TJ (1990) Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys 18: 873-878
4. Fowler JF, Kinsella TJ (1996) The limiting radiosensitization of tumours by S-phase sensitisers. Br J Cancer 74(Suppl): S294-S298
5. Goffman TE, Dachowski LJ, Bobo H, Oldfield EH, Steinberg SM, Cook J, Mitchell JB, Katz D, Smith R, Glatstein E (1992) Long-term follow-up on National Cancer Institute phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J Clin Oncol 10: 264-268
6. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Vile RG, Peters AM, Stewart JSW (2001a) Phase II study of pegylated liposomal doxorubicin (Caelyx™) in patients with inoperable, locally advanced squamous cell cancer of the head and neck. Eur J Cancer 37: 2015-2022
7. Harrington KJ, Lewanski CR, Stewart JSW (2000a) Liposomes as vehicles for targeted therapy of cancer. Part 1: Preclinical development. Clin Oncol (R Coll Radiol) 12: 2-15
8. Harrington KJ, Mohammadtaghi S, Uster PS, Glass DM, Peters AM, Vile RG, Stewart JSW (2001b) Effective targeting of solid tumours in patients with locally advanced cancers by radiolabelled pegylated liposomes. Clin Cancer Res 7: 243-254
9. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Peters AM, Uster PS, Vile RG, Stewart JSW (2000b) Pegylated liposome encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumour xenograft model. Clin Cancer Res 6: 4939-4949
10. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Uster PS, Abra RM, Stewart JSW (2000c) Biodistribution and pharmacokinetics of 111 In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targetting strategies. Br J Cancer 83: 232-238
11. Harrington KJ, Rowlinson-Busza G, Uster PS, Stewart JS (2000d) Pegylated liposome encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Cancer Chemother Pharmacol 46: 10-18
12. Henk JM (1997) Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity. Clin Oncol (R Coll Radiol) 9: 308-312
13. Huang SK, Lee K-D, Hong K, Friend DS, Papahadjopoulos D (1992) Microscopic localisation of sterically stabilised liposomes in colon carcinoma-bearing mice. Cancer Res 52: 5135-5143
14. Iliakis G, Kurtzman S, Pantelias G, Okayasu R (1989) Mechanism of radiosensitization by halogenated pyrimidines: effect of BrdU on radiation induction of DNA and chromosome damage and its correlation with cell killing. Radiat Res 119: 286-304
15. Kinsella TJ, Dobson PP, Mitchell JB, Fornace Jr AJ (1987) Enhancement of X-ray induced DNA damage by pre-treatment with halogenated pyrimidine analogs. Int J Radiat Oncol Biol Phys 13: 733-739
16. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retails G, Karkavitsas N, Helidonis ES (1999) Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 17: 3512-3521
17. Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD (1990) The dependence of halogenated pyrimidine incorporation and radio-sensitization on the duration of drug exposure. Int J Radiat Oncol Biol Phys 18: 1393-1398
18. McGinn CJ, Kinsella TJ (1992) The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumour cell repopulation. Semin Oncol 4: 21-28
19. Miller EM, Fowler JF, Kinsella TJ (1992) Radiosensitization by halogenated pyrimidines: I. Radiosensitization of human colon cancer cells by iododeoxyuridine. Radiat Res 131: 81-89
20. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumour activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987-993
21. Munro AJ (1995) An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71: 83-91
22. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomised phase III clinical trial. J Clin Oncol 16: 2445-2451
23. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen KA (1998) Randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46: 135-146
24. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ (1991) Sterically stabilised liposomes: improvements in pharmacokinetics and anti-tumour therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11464
25. Pignon JP, Bourhis J, Domengé C, Designé L (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355: 949-955
26. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicentre phase II trial. J Clin Oncol 15: 3185-3191
27. Robertson JM, Sondak VK, Weiss SA, Sussman JJ, Chang AE, Lawrence TS (1995) Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 31: 87-92
28. Saunders M, Dische S (1996) Clinical results of hypoxic cell radiosensitization from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer 74: S271-S278
29. Speth PA, Kinsella TJ, Chang AE, Klecker RW, Belanger K, Collins JM (1988) Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver. Clin Pharmacol Ther 44: 369-375
30. Stewart S, Jablonowski H, Goebel F-D, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ (1998) Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16: 683-691
31. Sullivan FJ, Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, Oldfield EH, Goffman TE, Kinsella TJ, Mitchell JB (1994) National Cancer Institute (Phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 30: 583-590
32. Tannock IF (1996) Treatment of cancer with radiation and drugs. J Clin Oncol 14: 3156-3174
33. Urtasun RC, Cosmatos D, DelRowe J, Kinsella TJ, Lester S, Wasserman T, Fulton DS (1993) Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys 27: 207-214
34. Urtasun RC, Kinsella TJ, Farnan N, DelRowe JD, Lester SG, Fulton DS (1996) Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, phase I-II study. Int J Radiat Oncol Biol Phys 36: 1163-1167
35. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (2nd edn). Br J Cancer 77: 1-10
36. Yagi T, Hisada R, Shibata H (1989) 3,4 Dinitrophenyl N-acetyl -β-D-glucosaminide, a synthetic substrate for direct spectrophotometric assay of N-acetyl-β-D-glucosaminidase or N-acetyl-β-D-hexosaminidase. Anal Biochem 183: 245-249